Skip to content
28 articles

Sciences

Life sciences, biotech, and research innovation.

Create content from your team’s expertise with free recording and AI writing tools. Qualifying companies also get one professional video edit a month. No credit card.

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes
Featured

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Retinitis pigmentosa has more than 90 causal genes. Celliaz's CLZ002 targets retinal repair, and Andelyn will make its plasmid and AAV2 vector.

MarketScale Newsroom·

All Articles

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Ten years of SR-Tiget's Just Like Home programme put numbers on what surrounds a gene therapy: long family stays, 15 years of checkups, a regulated lab.

MarketScale Newsroom·
Photonic AI hardware is now in outside testers' hands

Two photonic AI components reach outside testers—on limits

Q.ANT’s IONOS pilot and PsiQuantum switch samples put photonic hardware into limited outside testing as Kopin frees Massachusetts space for more manufacturing.

MarketScale Newsroom·
Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Goochland will make APIs and finished medicines on one campus. Virginia Business reports Lilly expects the first building to open in 2030.

MarketScale Newsroom·
Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Hiring fell to a net +2 outlook while consumables hit +30. What Lab Manager's fall survey means for anyone writing a 2027 lab budget request.

MarketScale Newsroom·
Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra's Building H in Bloomington adds three sterile filling lines for syringes and vials, as the CDMO plans to grow from 11 filling lines to 18 by 2027.

MarketScale Newsroom·
Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent's 5987A GC/MSD folds SIM and full-scan into one injection and widens dynamic range, a pitch that gains weight as helium prices climb.

MarketScale Newsroom·
Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's LiGeR-HN1 Phase 3 trial hit both primary endpoints in 699 first-line patients, with a hazard ratio of 0.50 regardless of HPV status.

MarketScale Newsroom·
UCB commits to Veeva Vault CRM for unified engagement

UCB commits to Veeva Vault CRM platform

UCB has committed to Veeva Vault CRM, which Veeva pitches as an agentic platform to drive unified engagement worldwide.

MarketScale Newsroom·
Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide pairs a GMP survey of peptide and oligo plants with a safety framework for the piping that stops being intuitive at scale.

MarketScale Newsroom·
Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

At Vitafoods Asia 2026, Astrion drew more booth interest than AstraGin, and NuLiv heard requests for probiotic strains built for pets, children and women.

MarketScale Newsroom·
Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

NuLiv Science expected AstraGin to lead at Vitafoods Asia 2026. Collagen-boosting Astrion drew the attention instead, backed by a 150-person skin trial.

MarketScale Newsroom·
Drug makers often sign CDMO renewals before they know when generics arrive

Drug makers often sign CDMO renewals before they know when generics arrive

Entresto sales fell 43% after US generic entry in 2025. Fixed CDMO batch minimums don't shrink when generics arrive. The sponsor still owes them.

MarketScale Newsroom·
Waters buys MOBILion to push into the $2 billion LC-MS proteomics market

Waters buys MOBILion to push into the $2 billion LC-MS proteomics market

Waters adds MOBILion's SLIM ion mobility to its mass specs as its existing business rose 9% to $871 million on routine testing demand.

MarketScale Newsroom·
With 51% of surveyed scientists stuck moving data between tools, what an ELN connects to is the real buying test

What an ELN connects to is the real buying test

As ELNs become standard, what an ELN entry connects to is the real buying test.

MarketScale Newsroom·
Takara Bio and SPT Labtech pair SMART-Seq kits with firefly automation scripts

Takara Bio and SPT Labtech pair SMART-Seq kits with firefly automation scripts

Shipping in January 2027, the SMART-Seq mRNA Long Read Extended kit is set to be the first product to launch with a firefly-optimized workflow.

MarketScale Newsroom·
Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck's €300 million Korean plant localizes cell culture media

Merck’s new Daejeon site makes cell culture media, process liquids and sterile sampling gear for Asia-Pacific biologics plants, from pre-GMP to commercial.

MarketScale Newsroom·
IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox forecasts 8%–12% annual QCL growth through 2035, tied to broader mid-infrared spectroscopy adoption.

MarketScale Newsroom·
Why a 1% auto-injector change still means redoing most of the work

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight's Fubin Wu says a shared auto-injector forces rebuilt design files; ISPE says no platform device pathway exists yet.

MarketScale Newsroom·
Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's Pingshan plant pairs sub-10 ms 5G, zero-touch AGVs and AI inspection to fill 330 million enoxaparin syringes a year on a land-scarce Shenzhen site.

MarketScale Newsroom·
Chalmers' AI scientist turned 60,000 yeast records into nearly 2,000 testable ideas

Chalmers' AI scientist turned 60,000 yeast records into nearly 2,000 testable ideas

Eve, a robot scientist at Chalmers, generated hypotheses, designed yeast experiments and revised its own ideas. Lab data readiness is the real test.

MarketScale Newsroom·
Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel and Warwick's Q-2DMS method reports up to tenfold more usable data on near-isobaric compounds, aiming to widen access to 2D mass spectrometry.

MarketScale Newsroom·
Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

FairJourney Bio's Maria Gonzalez-Pajuelo says developability has become a much more important consideration during antibody discovery.

MarketScale Newsroom·
AI shows up in all five tracks at ISPE's 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting chairs explain why AI has no track of its own—and why they expect it to show up across the five tracks, from discovery to governance.

MarketScale Newsroom·
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation

From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Payerwatch·
What Exactly Is a 5-Log Reduction, and Why Does It Matter for Cleanroom Teams

What Exactly Is a 5-Log Reduction, and Why Does It Matter for Cleanroom Teams

In cleanroom environments, contamination control isn’t about vague cleanliness—it’s about measurable reductions, and a 5-log reduction means cutting microbial presence by 99.999%, turning 100,000 bacteria into just one. For cleanroom teams, this level of performance before disinfectants are even applied is critical, because it dramatically lowers bioburden risk and strengthens the effectiveness of every…

William Sepsis·
My Biggest Takeaway from NC State’s Bioprocessing Course

My Biggest Takeaway from NC State’s Bioprocessing Course

Hands-on immersion has become a defining advantage in modern biomanufacturing, and programs like NC State’s BTEC exemplify why experiential learning matters as much as technical knowledge. By stepping through a full upstream and downstream bioprocess in a simulated environment, the Benchmark team gained firsthand insight into the real-world pressures, decisions, and constraints their customers…

Mary Kate Campbell·
Lamar IoT’s Cutting-Edge Tracking Tech Prevents Drugs & High-End Food Products from Perishing

Lamar IoT’s Cutting-Edge Tracking Tech Prevents Drugs & High-End Food Products from Perishing

Real-time condition monitoring prevents costly losses of temperature-sensitive pharmaceuticals and perishables across complex global supply chains

Mike Bush·

From the archive

New to MarketScale?

MarketScale is the B2B media platform Sciences companies use to publish their own experts. Create a free workspace with no credit card, or book a demo to see how it works for your team.